Reuters logo
BRIEF-Astrazeneca announced new results data evaluating cost-effectiveness of synagis
March 28, 2017 / 1:46 PM / 6 months ago

BRIEF-Astrazeneca announced new results data evaluating cost-effectiveness of synagis

March 28 (Reuters) - Astrazeneca Plc:

* Astrazeneca - announced new results data evaluating cost-effectiveness of synagis for respiratory syncytial virus in preterm infants 29-34 weeks gestational age

* Astrazeneca - results showed synagis may reduce overall costs in infants born at 29-32 weeks gestational age who are less than 3 months of age over 1-year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below